// App-Quantinova.ai

TPS2595 : A phase I, open-label study of GSK2816126, an enhancer of zeste homolog 2 (EZH2) inhibitor, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), other non-Hodgkins lymphomas (NHL), multiple myeloma (MM) and solid tumor.

Researchers

Presenter

  • Timothy Anthony Yap

Principal Investigators

  • Peter W. M. Johnson

  • Jane Winter

  • John Leonard

  • Lisa Giulino-Roth

  • Thierry Horner

  • Kristen Radswillas

  • Jennifer Carver

  • Arindam Dhar

Medical Centers

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Cancer Research UK, Southampton, United Kingdom

  • Feinberg School of Medicine, Northwestern University, Chicago, IL

  • Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY

  • Weill Cornell Medical College, New York, NY

  • GlaxoSmithKline, Collegeville, PA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • B-Cell Non-Hodgkin Lymphoma

  • Follicular lymphoma

  • Hodgkin's Lymphoma

  • Multiple Myeloma

  • B cell lymphomas

  • Solid malignancies

  • Lymphomas

Biomarkers

  • Enhancer of zeste homolog 2

Drug/Treatment

  • GSK2816126

  • EZH2

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT02082977

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved